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  Objective(s): P-glycoprotein (P-gp) is an efflux protein, the overexpression of which has been 
associated with multidrug resistance in various cancers. Although siRNA delivery to reverse P-gp 
expression may be promising for sensitizing of tumor cells to cytotoxic drugs, the therapeutic use 
of siRNA requires effective carriers that can deliver siRNA intracellularly with minimal toxicity on 
target cells. We investigated a special class of PEGylated lipid-based nanoparticles (NP), named 
nanolipoparticles (NLPs), for siRNA-mediated P-gp downregulation. 
Materials and Methods: NLPs were prepared based on low detergent dialysis method. After 
characterization, we evaluated the effect of NLPs on siRNA delivery, and P-gp downregulation 
compared to oligofectamineTM (OFA) in vitro and in vivo. 
Results: Our results showed a significant decrease in P-gp expression and subsequent 
enhancement of chemosensitivity to doxorubicin in vitro. Although the effectiveness of NLPs for in 
vitro siRNA delivery compared to OFA was limited, the results of in vivo studies showed noticeable 
effectiveness of NLPs for systemic siRNA delivery. siRNA delivery using NLPs could downregulate 
MDR1 in tumor cells more than 80%, while OFA had a reverse effect on MDR1 expression in vivo.  
Conclusion: The results indicated that the prepared NLPs could be suitable siRNA delivery 




Received: Aug 2, 2014 
















►Please cite this paper as: 
Nourbakhsh M, Jaafari MR, Lage H, Abnous Kh, mosaffa F, Badiee A, Behravan J. Nanolipoparticles-mediated MDR1 siRNA delivery reduces 
doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 







MDR1 is the gene that encodes P-glycoprotein             
(P-gp), and it’s over expression has been known as a 
mechanism of drug resistance in several cancer types 
such as breast cancer (1, 2). Due to the nonspecific 
toxic effects, there are very few chemical P-gp 
inhibitors that may be useful for clinical use (3). The 
discovery of RNA interference (RNAi) and the 
possibility of downregulation of P-gp by small 
interfering RNAs (siRNAs) provides new fields for 
further studies (4). Therapeutic application of siRNA 
requires developing efficient carriers that: 1) have high 
affinity for siRNA; 2) protect siRNA from degradation 
in vivo; 3) deliver siRNA to the target cells; 4) enhance 
cellular uptake and endosomal escape and finally 5) 
release siRNA inside the cell (5).  
In general, these problems can be partly overcome 
by forming complexes of siRNAs with cationic lipids or 
cationic polymers. However, in the presence of              
plasma proteins, the aggregation of positively            
charged complexes results in rapid elimination by 
reticuloendothelial system (RES) (half-life< 5 min)              
(6, 7). 
Based on these facts many scientists tried                  
to design new formulations with better properties 
for in vivo experiments. The liposomal nanoparticles 
with the general name of NP (7) are one of              
these new formulations for nucleic acid delivery.             
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encapsulated nucleic acids in a polyethylene glycol 
(PEG) -shielded bilayer shell have better stability               
in vivo (half-life: 1-10 hr) (8) compared with traditional 
lipoplexes. 
Nanolipoparticles (NLPs) as a member of NP group 
are PEGylated nanoliposomes designed by Li et al (8) in 
order to use in vivo gene delivery experiments. NLPs 
with small particle size (< 100 nm) and neutral charges 
have better stability in vivo and are suitable for in vitro 
and in vivo DNA delivery (7).  
Furthermore for an efficient tumor therapy, 
enhanced permeability and retention (EPR) effect 
can be exploited as a passive targeting phenomenon. 
Abnormal leaky tumor vessels and lack of efficient 
lymphatic drainage in tumors provide opportunity 
for nanoparticles to accumulate in tumor tissue 
much more than normal tissues (9). Small size and 
proximity to neutral surface charge of NLPs by 
reducing mononuclear phagocyte system (MPS) 
uptake enhance their circulation time and provide 
more opportunity for the EPR effect and passive 
accumulation in the tumor area. 
So far, there has been some success in P-gp 
knockdown by siRNA silencing; however, for clinical 
trial experiments, a systemic method of delivery of 
siRNA is needed (4). On the other hand, NLPs not 
only have shown high efficiency for gene delivery in 
vitro studies (7, 8), they also have a good potential 
for in vivo applications. Based on these facts, we 
exploited the PEGylated NLPs for MDR1 siRNA 
delivery.  
In our previous study, NLPs containing MDR1 siRNA 
were prepared based on low concentration detergent 
dialysis method (10). Liposomal characterization 
showed NLPs with the small size of 80 to 90 nm and the 
surface charge close to neutral, which had no toxicity on 
the MCF7/ADR cells. The encapsulation efficiency of 
siRNA in the NLPs was more than 80%. These results 
emphasize that the NLPs containing siRNA can be 
good candidates for in vivo studies and tumor 
targeting. We also demonstrated that the fluorescent 
siRNAs can be localized in MCF7/ADR cells, and the 
presence of serum in cell culture medium did not 
have any effects on siRNA localization (10). 
Therefore, NLPs containing MDR1 siRNA are suitable 
for more studies on multidrug resistance reversal in 
cancer therapy.  
In current study, we investigated the ability of NLPs 
containing MDR1 siRNA for multidrug resistance 
reversal in breast carcinoma, in vitro and in vivo.               
We evaluated the effects of NLP mediated MDR1 siRNA 
delivery on MDR1 gene downregulation and P-gp 
expression by real time RT-PCR and western blotting 
analysis, respectively. We also investigated 
chemosensitivity enhancement to doxorubicin in MCF-
7/ADR cells. After initial in vitro studies, NLPs were 
tested for tumor therapy in vivo.     
 
Materials and Methods 
Materials 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethelene glycol)-2000] (mPEG             
2000-DSPE), 1,2-Dioleoyl-3-Trimethylammonium-
Propane (DOTAP), 1,2-Dioleoyl-sn-Glycero-3-Phospho- 
ethanolamine (DOPE) were from Avanti Polar Lipids 
(Alabaster, AL, USA). Octyl β-D-glucopyranoside             
(OG) and Tris (hydroxymethyl)aminomethane and              
Diethyl pyrocarbonate (DEPC) were purchased                
from Invitrogen™ (USA). Oligofectamine™ (OFA) 
transfection reagent was purchased from Invitrogen™ 
(USA). All other chemicals used were of molecular 
grade. Deionized water was used in all experiments and 
then treated with DEPC for siRNA containing samples.   
 
siRNAs 
The anti-MDR1-specific siRNA duplex (siM) 
homologous to nt 88 to 108 (sense strand 5'-GAA ACC 
AAC UGU CAG UGU AdTdT-3’) was previously designed 
against the MDR1-encoding mRNA consensus sequence 
(GenBank accession number no. NM_000927) (11). In 
addition, a biologically active siRNA 5’-CGU ACG CGG 
AAU ACU UCG AdTdT-3’ directed against the non-
mammalian luciferase (GL-2) encoding mRNA (siC) was 
used as a negative control. Both siRNAs were 
commercially obtained from Dharmacon (Lafayette, CO, 
USA) in annealed form. 
 
Preparation and characterization of NLPs 
containing siRNA  
siRNA was encapsulated into NLPs by the detergent 
dialysis method and characterized                   as 
described before (10). Briefly, mPEG- DSPE/- 
DOTAP/DOPE were mixed at a molar ratio 10/50/40 in 
chloroform, dried by rotary evaporation and placed 
under a high vacuum for 2 hr. Then, the dried lipid film 
was hydrated in 1.47 ml of 28 mM OG in 5 mM Tris 
buffer (pH 8.0) for 30 min. 14881pmol siRNA was 
separately solubilized in 1.47 ml of 28 mM OG in 5 
mM Tris buffer (pH 8.0). The latter solution was 
gently added into the lipid solution and vortexed for 
30 sec. Following 10 min incubation at room 
temperature for spontaneous particle formation,  the 
mixture was transferred to a Slide-A-LyzerTM dialysis 
cassette (MWCO 10 K; Pierce, Rockford, IL, USA) and 
dialyzed against 1 L of 5 mM Tris buffer (pH 8.0) for 
2 days at 4°C. For the in vitro and in vivo studies, the 
buffer was changed to150 mM NaCl, 5 mM Tris 
buffer (pH 8.0) by dialysis. 
 
Cell lines and cell culture 
Human breast carcinoma cell line MCF-7 and 
established classical multidrug-resistant, P-gp-positive 
derivative, MCF-7/ADR (from Lage's laboratory stocks) 
were grown as described (10). 
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Cell transfection 
For cell transfection with NLPs and OFA (as a 
positive control), MCF-7/ADR Cells (3 ×105/well) were 
plated in six-well plates. The cells were then transfected 
at 30 to 40% confluence (10, 11). Transfection was 
performed in OPTI-MEM1 (Invitrogen™, USA) without 
serum or antibiotics in a final volume of 1 ml. In the 
case of NLPs, final concentrations of siRNA were 
calculated based on siRNA concentration in the 
formulation (5 µM). After 4 hr incubation at 37 °C, FBS 
(10% final concentration) was added.  
 
Quantitative real-time RT-PCR analysis of MDR1 
mRNA 
MCF-7/ADR cells were transfected with liposomes 
containing siM (At 25, 50 and 100 nM concentrations) 
or with liposomes containing siC (100 nM) and empty 
liposomes (At lipid concentrations equivalent to                 
100 nM loaded liposomes). Each experiment was 
performed in triplicate. Total RNA was extracted from 
MCF-7 parental line, untreated MCF-7/ADR and all 
transfected groups 24 and 48 hr after transfection with 
a RNA extraction kit (RNeasy mini kit, Qiagen, 
Germany) according to the manufacturer protocol,            
and purity and integrity of RNAs were tested by 
measuring A260/A280 and running on 1% agarose gel, 
respectively. 
 After synthesizing cDNA using SuperScript™ First-
Strand Synthesis System for RT-PCR (Invitrogen™, 
GmbH), real time PCR was carried out using 
LightCycler® Fast Start DNA Master SYBR Green I and 
the LightCycler 1.5  instrument  (Roche Diagnostics, 
Mannheim, Germany) as Mosaffa et al described (12). 
All reactions were performed in duplicate. The forward 
and reversed primer sequences for MDR1 and β-actin 
genes (as a housekeeping gene) were; Primer F MDR1: 
5'-CCC ATC ATT GCA ATA GCA GG -3'; Primer R MDR1: 
5'-TGT TCA AAC TTC TGC TCC TGA -3' (amplification 
product of 158 bp); Primer F β-actin: 5'-TCA TGA AGT 
GTG ACG TGG ACA TC -3' and Primer R β- actin 5'-CAG 
GAG GAG CAA TGA TCT TGA TCT-3' (amplification 
product of 156  bp); (MWG GmbH,Germany). Primers 
were chosen according to previous studies (13, 14). 
Melting curve analysis was performed to analyze 
quality of primers and products. Expression of target 
genes was normalized against β-actin. ΔΔCT method 
was used to measure fold increase of genes in 
compare to control group. 
 
Western blot analysis  
The total protein contents of NLP siM and OFA 
siM transfected groups were extracted after 48, 72 
and 96 hr. Protein extraction for control groups was 
carried out after 48 hr. To prepare cell lysate, the cell 
culture plate was placed on ice, cells were washed 
with 1 x PBS and mixed with P38 buffer (Tris-HCl 
(62.5 mM), SDS (2% W/V), glycerol (10% W/V), DTT 
(50 mM) in protease inhibitor pretreated nuclease-
free water (half of the complete protease inhibitor 
cocktail tablet (Roche) dissolved in 25 ml of double 
distilled water). The protein concentration was 
determined using the Pierce BCA Protein Assay Kit 
(Pierce, Rockford, IL, USA) according to the 
manufacturer’s protocol. Then cellular levels of 
MDR1/P-gp, in different experimental groups were 
analysed by western blotting as Stege et al described 
(15). MDR1/P-gp proteins were detected using a 
mouse monoclonal antibody (mAbs) C219 (Alexis, 
San Diego, CA, USA). We used mouse mAb against 
actin (mAb 1501 R; Chemicon, Temecula, CA) as a 
loading control and peroxidase-conjugated goat anti- 
mouse IgG (A-1949; Sigma, St. Louis, MO, USA) as a 
secondary antibody. Finally, protein bands were 
analyzed using UVtec software (UK). Experiments 
performed in triplicate. 
 
MTT assay for chemosensitivity enhancement 
determination 
To evaluate the level of chemosensitivity 
enhancement following two days of siRNA transfection, 
MCF-7/ADR cells were incubated with 10 µM 
doxorubicin for 48 hr and the percentages of viable 
cells in different transfected groups was compared to 
untransfected control group as determined by MTT 
assay (16). Each assay was carried out in triplicate. 
 
Animals for in vivo studies 
Four-to-eight week-old female BALB/c mice were 
purchased from Pasteur Institute (Tehran, Iran). Mice 
were maintained in animal house of Pharmaceutical 
Research Center (MUMS, Iran) and fed with tap water 
and laboratory pellet chow (Khorassan Javane Co, 
Mashhad, Iran). Animals were housed in a colony room 
12/12 hr light/dark cycle at 21 °C and had free access to 
water and food. All animal experiments were 
performed in compliance with the Institutional Ethical 
Committee and Research Advisory Committee of 
Mashhad University of Medical Sciences guidelines 
(Education Office, dated June 3, 2009; proposal code 
87890).  
 
Development of MCF-7/ADR tumor xenograft in mice  
To achieve appropriate MCF-7/ADR xenograft 
tumor size in female BALB/c mice, in a pilot study, 
different immunosuppressors with different doses 
were studied (17-20). Finally, mice were immune-
suppressed by intraperitoneal injection of 150 mg/kg 
cyclophosphamide (Baxter, Germany) on two 
consecutive days. Mice were inoculated subcuta-
neously with 107 MCF-7/ADR cells on the third day. 
They received 25 μg of β-estradiol 17-valerate 
(Aburaihan Pharmaceutical co., Iran) (dissolved in 
50 µl of sesame oil (Sigma, USA)), simultaneously. 
Tumor sizes were assessed every other day.             
When the tumor grew to approximately 5 to 7 mm in 
diameter, mice were divided into 5 groups, three 
mice/groups, including a normal saline treated 
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group (NS), an NLP control siRNA treated group 
(NLP siC 1.6 mg/kg), two NLP MDR1 siRNA treated 
group (NLP siM 0.8 mg/kg and NLP siM 1.6 mg/kg), 
and an oligofectamine MDR1 siRNA treated group 
(OFA siM 1.6 mg/kg). All the mice were injected 
intravenously, and the volume of injection was 
adjusted to 200 µl.  
 
Quantitative real-time RT-PCR for MDR1 mRNA 
detection in tumors 
Tumor tissues were isolated 48 hr after siRNA 
administration and immediately frozen in liquid 
nitrogen for subsequent MDR1 mRNA level analysis. 
Total RNAs were extracted from all tumors using a 
tissue RNA extraction kit (High Pure RNA Tissue Kit, 
Roche) as described in the manufacturer's protocol 
and real time PCR analysis carried out as described. 
 
Statistical analysis 
One-way ANOVA statistical test was used to 
assess the significance of the differences between the 
various groups. Tukey test was used to compare the 
means of different treatment groups in in vitro 
studies. In the case of in vivo studies, t test was used 
to compare each group with NS control group.               
P<0.05 was considered statistically significant.  
 
Results 
The effects of NLP siM on MDR1 mRNA expression  
To assess multidrug resistance expression in 
MCF7/ADR cell line, we compared the levels of MDR1 
mRNA expression in MCF7/ADR and its parental 
MCF-7. We observed that the levels of MDR1 mRNA 
in MCF7/ADR cells were about ten times more than 
its parental MCF-7 (Figure 1). At the next step, 
relative MDR1 mRNA expression was evaluated at 24 
and 48 hr after transfection by real-time RT-PCR 
analysis. NLP siM and the positive control (OFA siM), 
significantly inhibited MDR1 expression in all 
concentrations at 24  and 48 hr (P<0.001) (Figure 2). 
Maximum MDR1 mRNA reductions were about 
30.5% and 68.3% as obtained by NLP siM and OFA 




Figure 1. Relative mRNA levels for MDR1 in MCF-7/ADR human 
multidrug-resistant breast cancer cells and their parental cells 
MCF-7. The MDR1 mRNA expression value was normalized to             
β-actin. Data are means±SEM. (n = 3; *** P<0.001) 
In the negative controls, although empty NLP had no 
significant effects on MDR1 expression, NLP siC 
reduced significantly MDR1 expression by 11.5% at 
48 hr (P<0.05).  Meanwhile, empty OFA and OFA siC 
significantly increased MDR1 mRNA expression by 






















Figure 2. Relative mRNA levels for MDR1 in MCF-7/ADR human 
multidrug-resistant breast cancer cells. MCF-7/ADR Cells 
transfected with different formulations and incubated for 24 or 48 
hr. MDR1 mRNA downregulation efficiency was calculated by 
comparing the MDR1 mRNA expression value in each transfected 
group to the untreated group. The MDR1 mRNA expression value 
was normalized to β-actin. Data are means±SEM. (n=3; *P<0.05, 
*** P<0.001)  
NLP: Nanolipoparticle; OFA: Oligofectamine; siC: Control siRNA; 





Figure 3. Western blot assay to determine the effect of MDR1 
siRNA loaded nanoparticles on the P-gp expression. MCF-7/ADR 
Cells transfected with different  formulations at the 100 nM and 
incubated for 48, 72 or 96 hr. P-gp downregulation efficiency was 
calculated by comparing the level of P-gp expression in each 
transfected group to the untreated group. (A) Top: P-glycoprotein 
was detected with C219 antibody. Bottom: The same membrane 
was reprobed with anti-actin antibody. (B) The quantitation of 
Western blot images carried out by using UVtec software and the 
protein levels were normalized against actin intensity. Data are 
means±SEM (n= 3; ** P<0.01, *** P<0.001).  
NLP: Nanolipoparticle; OFA: Oligofectamine; siC: Control siRNA; 
siM: MDR1 siRNA 
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Downregulation of P-glycoprotein expression 
using NLP siM 
For the evaluation of NLP siM efficacy in reversal 
of P-glycoprotein expression, western blotting                
was carried out on proteins extracted from different  
treated cells. MCF-7/ADR cells treated with NLP and 
OFA containing 100 nM siM or siC and with empty 
liposomes at equal concentration of lipid. Untreated 
MCF-7/ADR cells were used as the reference for 
resistant cells. As shown in Figure 3, significant 
decreases in P-gp expression (31.32 and 23.1%) 
were observed in NLP siM transfected cells after 72 
and 96 hr (P<0.001), respectively. OFA siM 100 nM, 
positive control, could significantly reduce P-gp 
expression after 48 (P<0.01), 72 and 96 hr (P< 0.001) 
and maximum inhibition was obtained after 72 hr 
(57.7%), and remained nearly the same at 96 hr 
(53.3%). No significant effect observed in NLP siC and 
OFA siC treated groups. Interestingly, empty NLP and 
empty OFA significantly increased P-gp expression by 
27.2% (P<0.001) and 30.9% (P<0.01), respectively.  
 
Chemosensitivity enhancement in MCF-7/ADR cells 
MCF-7/ADR cells were pretreated with NLP siM 100 
nM, empty NLP (as a negative control), NLP siC (as a 
negative control) and OFA siM 100 nM (as a positive 
control). Forty eight hours after transfection, cells were 
incubated with different concentrations of doxorubicin 
(1, 10 and 100 µM) for 24 and 48 hr. Treatment with 10 
µM doxorubicin for 48 hr was chosen as an appropriate 
incubation time and concentration for maximum 
discrimination between liposome siRNA treated and 
untreated cells. Figure 4 shows the viability of different 
transfected MCF-7/ADR cells relative to the non-
transfected control MCF-7/ADR cells after 48 hr 
incubation with 10 µM doxorubicin. The percentage of 
chemosensitivity enhancement was calculated as the 
decrease of cell viability percentage (Equation 2).   
 
Equation 2 chemosensitivity enhancement % = 100 - 
% cell viability.  
 
NLP siM 100 nM led to significant 26.7% 
chemosensitivity enhancement (cell viability decrease 
to 73.3±4.1 (P< 0.01)), whereas OFA siM 100 nM as a 
positive control increased chemo-sensitivity to 
doxorubicin to 60.2% (cell viability decrease to 
39.7±1.9% (P<0.001)). NLP siC 100 nM and empty NLP 
as a negative controls did not have any significant 
effects on chemosensitivity enhancement (P>0.05). 
 
Downregulation of MDR1 mRNA expression in tumors 
In order to confirm that siRNA may be delivered 
to the target cells in tumor tissue through systemic 
administration of NLPs, we assessed the effects of 
the siM on MDR1 gene expression in tumors. We 
determined NLP siM gene silencing efficiency in 
tumors (Figure 5). We found that NLP siM with the  low 
dose of 0.8 mg/kg had no significant effect on             
MDR1 gene expression; however, by a dose increase  to             
1.6 mg/kg, significant gene silencing effect              
(80.9%±6.93 (P<0.001)) was observed. It is interes-ting 
that in control group, NlP siC, significantly enhanced 
MDR1 gene expression (about 82.5%±17.81 (P<0.01)). 
Similarly, in the case of OFA siM we observed 
significant MDR1 gene expression enhancing effect 





Figure 4. Enhancement of chemosensitivity to doxorubicin. 
Cytotoxicity of doxorubicin in MCF-7/ADR cells was assessed by 
MTT. Untransfected cells (control), cells transfected with 
liposomes containing MDR1 siRNA 100 nM (NLP siM, OFA siM) or 
cells transfected with empty NLP (NLP) or NLP containing control 
siRNA 100 nM (NLP siC) (as negative controls). After 48 hr, cells 
were incubated with 10 µM doxorubicin for 48 hr. Relative cell 
viability compared with control group has been reported. Data are 
means±SEM (n=3; ** P<0.01, *** P<0.001). 
 NLP: Nanolipoparticle; OFA: Oligofectamine; siC: Control siRNA; 




Figure 5. Functionality of nanolipoparticles containing MDR1 
siRNA (NLP siM) and OFA siM in mice. 48 hr after systemic 
administration of formulated NLP siRNAs (0.8 and 1.6 mg/kg siM; 
1.6 mg/kg siC) and OFA siM (1.6 mg/kg), tumor tissues harvested 
and total RNA was extracted for real-time RT-PCR analysis. The 
mRNA levels are shown relative to the control group (NS). The 
mRNA levels of MDR1 gene were normalized to the β-actin mRNA. 
Eeach group contained 3 mice and the reactions were performed 
in duplicate. The values are means ± SEM (*P<0.05, ** P<0.01, *** 
P<0.001)  
NLP: Nanolipoparticle; siC: Control siRNA; siM: MDR1 siRNA; NS: 
Normal saline 
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Discussion  
Non-toxic, suitable siRNA loaded NLPs with the 
stable size of 80 to 90 nm and the surface charge close 
to neutral (10). PEGylation by shielding positive surface 
charge of the particles and reducing their interactions 
enhance the stability and RES escape ability of the 
particles in vivo. Accomplishment of small size (less 
than 150 nm) with these characteristics results in 
circulation time enhancement and helps to exploit the 
EPR effect for passive targeting in cancer therapy (7). 
NLPs have all these characteristic properties making 
them suitable candidates for passive tumor targeting by 
EPR mechanism.  
The effectiveness of MDR1 siRNA (siM) for P-gp 
downregulation was confirmed with oligofectamineTM 
(OFA) transfection. OFA as a good model of                            
the commercial traditional liopoplexes has been 
frequently used for siRNA mediated P-gp 
downregulation (11). We evaluated MDR1 siRNA (siM) 
effects on P-gp downregulation in MCF-7/ADR cell line 
and compared siRNA delivery efficiency of NLP and 
OFA in vitro.  
The assessment of MDR1 gene expression 
demonstrated that OFA siM and NLP siM even in low 
dose (25 nM) significantly reduced MDR1 gene 
expression at 24 and 48 hr. MDR1 gene silencing by 
NLP siM was accompanied by significant total P-gp 
downregulation at 72 and 96 hr. This 24 hr gap 
between mRNA and protein downregulation may 
have been resulted from P-gp long half-life (about 
14-17 hr) (21). After 72 hr of treatment, the P-gp 
content started to increase again, and that can be 
explained by transient effects of siRNA. On the                
other hand, we observed significant MDR1 gene 
downregulation in NLP siC treated groups after 48 hr. 
This effect of NLP siC can be explained by off target 
effects of luciferase control siRNA. It has been reported 
that luciferase siRNA could remarkably increase or 
decrease the gene expression of about 2000 genes 
among 3300 genes in mammalian cells (22). 
In order to confirm reversal of the MDR 
phenotype in MCF-7/ADR cells, chemosensitivity 
enhancement to doxorubicin analysis was used. NLP 
siM 100 nM significantly enhanced chemosensitivity 
to 10 µM doxorubicin in MCF-7/ADR cell line. 
Therefore, NLP siM could downregulate P-gp 
expression in vitro successfully, but its effects were 
less than OFA. High PEG in our formulation, 10% 
molar ratio, may be the cause for less efficiency of 
NLPs compared to OFA. PEG is a biocompatible and 
inert polymer, which can reduce interaction of 
nanoparticles with the cell membrane (23). The 
higher amounts of PEG present in our formulation 
might have reduced the delivery of siRNA in vitro. 
Nevertheless, PEGylation could considerably 
improve gene transfer and the safety of the delivery 
system in vivo via extension of circulation time, 
reduction of toxicity and stabilizing the particle PEG-
lipid (24). It has been shown that increasing of 
mPEG-DSPE molar ratio in lipid DNA particles (LDPs) 
can reduce DNA delivery to B16/BL6 cells. It should 
be noted however, that this group did not test LDPs 
in vivo (25).  
In order to overcome multidrug resistance in 
tumors via systemic siRNA administration, we 
developed an MCF-7/ADR xenograft tumor in 
BALB/c mice and tested the NLP formulation for 
siRNA silencing effects and compared the results to 
those of OFA in vivo. In the case of OFA siM and NLP 
siC control groups surprisingly; we observed the 
opposite effects on MDR1 expression as they 
increased MDR1 mRNA expression in vivo. These 
observations might be explained by two facts. First, it 
has been demonstrated that synthetic siRNA can act 
as a potent activator for innate immune system and 
induce a high level of IFN-α and inflammatory 
cytokines in mammalian cells, especially when 
carried by lipidic or policationic carriers (26, 27). 
Secondly, IFN-α can induce an increase in P-gp 
expression, that is accompanied by MDR1 mRNA 
increase (28). We suggest that NLP siC has                     
no remarkable ability for MDR1 gene silencing, and 
OFA is not able to deliver the siM to tumors, 
Therefore, NLP siC and OFA siM could not silence the 
MDR1 expression efficiently, but might have            
up-regulated the MDR1 gene expression via innate 
immune stimulation. Furthermore, adding 
formulated liposomes to the cells may increase gene 
expression by unknown mechanisms (29).  We 
observed the enhancement of MDR1 mRNA and P-gp 
expression after incubation with empty NLP, empty 
OFA and OFA siC treated cells in vitro. Since NLP siC 
in spite of OFA siC did not increase the MDR1 or P-gp 
expression in vitro, we can conclude that OFA 
compared to NLP may have had a more stimulating 
effect on cells.  
In the case of NLP siM, although we could not see 
any significant effects at 0.8 mg/kg; however, 
intravenous administration of 1.6 mg/kg NLP siM 
could downregulate MDR1 mRNA more than 80%, 
while up to now just a limited number of                   
groups could successfully downregulate P-gp via 
systemic administration of siRNA. For example, 
exploitation 2 and 4% PEGylated liposomes in 
MCF7/A xenograft tumors results in a significant P-
gp downregulation (30). The P-gp downregulation 
was enhanced up to %60 by RGD modification of the 
PEGylated liposomes. This is while these liposomes 
have positive charge and their toxicity is more than 
NLPs toxicity. In another nonviral delivery approach, 
Patil et al (31) reduced the growth of JC breast 
cancer tumors in BALB/c mice to 50% with a single 
systemic injection of biotin-decorated poly(D,L-
lactide-co-glycolide) nanoparticles.  
Although a few studies have focused on systemic 
P-gp downregulation by nanoliposomes (30, 31), 
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there are some reports of successful systemic siRNA 
administration by PEGylated nanoliposomes in 
animals (32, 33). It has been reported that siRNAs 
encapsulated in stable nucleic acid lipid particles 
(SNALP) remarkably downregulate target gene in 
non-human primates (33). They siRNA administered 
dose was 1 or 2.5 mg/kg wich results in more than 
90% apolipoprotein B (APOB) gene silencing after 48 
hr. In another attempt for systemic siRNA delivery, 
one research group could downregulate the 
expression of E6/7 oncogenes to around 50% in 
cervical cancer tumors. They exploited the hydration-
of-freeze-dried-matrix (HFDM) method (34) to entrap 
siRNA within PEGylated liposomes. In these two 
studies, SNALP and HFDM-formulated particles 
contained 10% molar ratio PEG-S-DSG (C18) or 
PEG2000-C16 Ceramide. Although the presence of 
longer lipid anchors and higher PEG molar ratio in lipid 
based formulations could reduce cell interaction and 
transfection in vitro, they may increase tumor delivery 
because of more stability and more time in blood 
circulation. These theories may justify our findings. 
Existence of 10% mPEG-DSPE (C18) in NLP reduces in 
vitro cell transfection compared to non PEGylated 
liposomal OFA. However, systemic administration of 
NLPs containing MDR1 siRNA could downregulate 
significantly P-gp in tumor. These NLPs have small size 
and neutral surface charge; therefore, they have long 
circulation time in blood and can accumulate in tumor 
by EPR mechanism. Meanwhile, accumulation in tumor 
environment may provide enough time for NLPs to lose 
some of their PEG-lipids, and also due to the acidic pH 
of the tumor environment liposomes will be more 
positively charged compared to physiologic pH of 7.4, 
and therefore have more cell interaction compared to in 
vitro experiments.  
 
Conclusion 
In this study we prepared PEGylated 
nanoliposomes NLPs containing MDR1 siRNA based 
on detergent dialysis method. In order to investigate 
the ability of NLPs for siRNA delivery to tumors, the 
effects of NLP siM on MDR1 gene silencing were 
evaluated in vitro and in vivo. We observed that the 
NLPs delivered siRNA into MCF7/ADR cancer cells 
and tumors effectively. The NLP was more successful 
in delivery of siRNA into tumors compared to the 
traditional lipoplex, oligofectamineTM.  
In vivo anti-tumor activity of the NLP-siRNA in 
animal tumor model is under investigation. For 
further NLP siRNA delivery improvement, adding 
tumor targeting ligands or exchanging the PEGylated 
lipid to more removable PEG-lipids or pH-sensitive 
PEG-lipid can be exploited in future studies.  
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